Compare

Cel-Sci Corp vs Champions Oncology, Inc. vs Pluri Inc. vs Inmune Bio, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearCel-Sci Corp
CVM
Champions Oncology, Inc.
CSBR
Pluri Inc.
PLUR
Inmune Bio, Inc.
INMB
Year ended2025-09-302026-04-302026-06-302025-12-31
Revenuen/a$59.42M$1.02M$50.0K
Revenue growth (YoY)n/a+4.4%-24.0%+257.1%
Gross marginn/a48.0% (computed)44.6%n/a
Operating marginn/a-1.9%n/mn/m
Net marginn/a-2.0%n/mn/m
Net income-$25.41M-$1.18M-$23.82M-$45.93M
EPS (Diluted)-$6.27-$0.08-$2.44-$1.86
Operating cash flow-$17.12M-$4.47M-$19.59M-$22.58M
Free cash flow-$17.16M-$5.04M-$20.22M-$23.62M
Cash & equivalentsn/an/a$3.53M$24.75M
Total assets$28.16M$26.99M$24.88M$32.35M
Total liabilities$12.20M$22.92Mn/a$8.83M
Shareholders' equity$15.96M$3.94M-$23.04M$23.52M
Return on year-end equity-159.2%-29.8%n/a-195.3%
Shares outstanding8.02M13.89M10.82M26.59M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearCel-Sci CorpChampions Oncology, Inc.Pluri Inc.Inmune Bio, Inc.
Latest$264.0K
Ended 2014-09-30
$59.42M
Ended 2026-04-30
$1.02M
Ended 2026-06-30
$50.0K
Ended 2025-12-31
1 year earlier$159.6K
Ended 2013-09-30
$56.94M
Ended 2025-04-30
$1.34M
Ended 2025-06-30
$14.0K
Ended 2024-12-31
2 years earlier$254.6K
Ended 2012-09-30
$50.16M
Ended 2024-04-30
$326.0K
Ended 2024-06-30
$155.0K
Ended 2023-12-31
3 years earlier$956.2K
Ended 2011-09-30
$53.87M
Ended 2023-04-30
$287.0K
Ended 2023-06-30
$374.0K
Ended 2022-12-31
4 years earliern/a$49.11M
Ended 2022-04-30
$234.0K
Ended 2022-06-30
$181.0K
Ended 2021-12-31